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Prognostic Significance of C-Reactive Protein and Smoking
in Patients with Advanced Non-small Cell Lung Cancer
Treated with First-Line Palliative Chemotherapy
Andrea Koch, MD,*†‡ Helena Fohlin, MSc,§ and Sverre So¨renson, MD, PhD†‡
Hypothesis: The objective of the study was to analyze if C-reactive
protein (CRP) and smoking status provide prognostic information in
patients with advanced non-small cell lung cancer (NSCLC) receiv-
ing palliative first-line chemotherapy.
Methods: Retrospective, single-institutional study, comprising all
patients with NSCLC stage IIIB/IV and World Health Organization
performance status (PS) 0–2 who started palliative first-line chemo-
therapy between January 1, 2002, and January 31, 2007. Patient
records were reviewed. Cox’s proportional hazards model was used
to identify prognostic factors.
Results: Two hundred eight-nine consecutive patients were evalu-
able. Sixty-eight percent had stage IV disease and 67% had PS 0 or
1. Median survival was 7.4 months. At onset of chemotherapy, 206
patients (71%) had elevated CRP values (10 mg/liter). One-
hundred-forty-four patients (50%) were current smokers. On univar-
iate analysis, patients with elevated CRP levels had inferior survival
(hazard ratio [HR] 1.67, 95% confidence interval [CI], 1.28–2.19,
p  0.001). Smoking at onset of treatment was associated with
shorter survival (HR 1.56, 95% CI, 1.22–1.98, p  0.001). Ever
smokers had shorter survival than never smokers (HR 1.80, 95% CI,
1.25–2.59, p  0.001). On multivariate analysis, with stage, PS,
albumin, and gender as covariates, both smoking at start of chemo-
therapy and CRP elevation were independent negative prognostic
factors for survival.
Conclusions: CRP and smoking status are independent prognostic
factors for survival in patients with advanced NSCLC receiving
palliative first-line chemotherapy and provide additional information
to established prognostic factors such as stage of disease and
performance status.
Key Words: NSCLC, C-reactive protein, Smoking, Prognostic
factors, Palliative treatment.
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Lung cancer is the leading cause of death from cancer inEurope accounting for approximately 335,000 deaths in
2006.1 The majority of patients presents with locally ad-
vanced or metastatic disease (stage IIIB/IV) and is treated
with palliative intent.2
Prognostic factors can contribute to clinical decision
making and help to individualize treatment in this heteroge-
neous patient population. A great number of prognostic
factors in lung cancer have been described. In a systematic
review of the literature published between 1990 and 2001,
Brundage et al.3 found 169 prognostic factors described in
887 articles, regarding survival of patients with non-small
cell lung cancer (NSCLC). Most of these factors are, how-
ever, not readily available in routine clinical practice.
A causal relationship between inflammation and cancer
has been described.4 C-reactive protein (CRP) was discov-
ered in 1930 and is widely used as s sensitive, but nonspe-
cific, marker of systemic inflammation.5–7 Elevated levels of
circulating CRP, defined as CRP 10 mg/liter, have been
found in 75% to 80% of patients with inoperable NSCLC.8,9
The significance of CRP as a negative prognostic factor has
been shown in patients with several malignancies, i.e., mul-
tiple myeloma,10 melanoma,11 renal cell carcinoma,12 pros-
tate cancer,13 and gastrointestinal cancer.14,15
CRP is an inexpensive, readily available marker which
is analyzed routinely in lung cancer patients at our hospital.
In 203 patients who underwent curative resection of NSCLC,
preoperative serum CRP level was an independent predictor
of survival.16 Surprisingly, only few studies have analyzed
CRP as a prognostic factor in advanced NSCLC. Forrest et
al.17 found that CRP was a prognostic factor in 161 patients
with inoperable NSCLC. Patients received chemotherapy
and/or radical radiotherapy or supportive treatment. An in-
crease in the magnitude of inflammation, represented by
elevation of CRP levels, was associated with shorter survival,
increased weight loss and poorer quality of life in a study of
106 patients with stage III and IV NSCLC.9,18 No information
on the treatment given was available.
Smoking has been described as a prognostic factor in
lung cancer.19–21 Survival data related to smoking status were
presented in a randomized phase III study which compared
pemetrexed  cisplatin with gemcitabine  cisplatin in
patients with advanced NSCLC. Former/current smokers had
a significantly higher risk of death compared with never-
smokers (hazard ratio [HR]  1.74).22
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However, the majority of the studies included patients
with various stages and type of treatment was not taken into
consideration.19,23
The purpose of this study was to analyze if CRP and
smoking at start of treatment are prognostic factors for
survival in patients with advanced NSCLC treated with pal-
liative chemotherapy.
PATIENTS AND METHODS
Methods
All patients with NSCLC stage IIIB/IV who started
first-line chemotherapy from January 1, 2002 to January 31,
2007 were identified with help of our local patient registry.
This registry started on January 1, 2002 and contains data
about all patients treated with chemotherapy at the Depart-
ment of Pulmonary Medicine, University Hospital, Linko¨p-
ing, Sweden. A review of all patient records was performed.
Only patients treated with palliative intent were included.
Demographic and clinical data (age, gender, histologic
or cytologic tumor type, performance status (PS),24 disease
stage), date for start of chemotherapy, type of chemotherapy
and information on use of antibiotics were collected.
Smoking status at start of chemotherapy was registered.
Patients were classified into 3 categories: (1) current smokers,
(2) former smokers, and (3) never-smokers. A current smoker
was defined as a person who smoked every week or who had
stopped smoking within the last 12 months. A former smoker
was defined as a person who had stopped smoking 12
months before the start of treatment. A never-smoker was
defined as one who had never smoked and who was stated as
never-smoker in the patient record.
Among routine laboratory analyses made at onset of
chemotherapy, plasma-CRP, hemoglobin, white cell count,
lactate dehydrogenase, and albumin were recorded for the
purpose of this analysis. Only blood samples taken 1 week
before start of chemotherapy were considered. CRP was
measured with a turbidimetric method.
Patients with missing CRP values, missing information
on smoking status and patients in World Health Organization
PS 3 were excluded from analysis.
Statistical Analysis
Overall survival was defined as the time from start of
treatment to death from any cause. Deaths until March 31,
2008 were included in the analysis. Follow-up time was
defined as time from start of treatment until last observation
March 31, 2008. Survival analysis was performed using the
Kaplan-Meier method. Differences were assessed using the
log-rank test. To identify prognostic factors, Cox’s propor-
tional hazards model was used for univariate and multivariate
analyses. To analyze if CRP and smoking were independent
predictors of survival, a multivariate analysis with tumor
FIGURE 1. Exclusions after identification of 313 patients
with non-small cell lung cancer (NSCLC) stage IIIB/IV treated
with palliative first-line chemotherapy.
TABLE 1. Patient Characteristics (n  289)
No. of Patients Percent
Gender
Male 158 55
Female 131 45
Smoking status
Current smoker 144 50
Former smoker 105 36
Never-smoker 40 14
Performance status
0–1 194 67
2 95 33
Tumor type
Adenocarcinoma 141 49
Squamous cell carcinoma 37 13
Other 111 38
Stage
IIIB 93 32
IV 196 68
Treatment
Carboplatin  gemcitabine 205 71
Carboplatin  vinorelbine 47 16
Other two-drug regimen 21 7
Single-drug 16 6
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stage, PS, albumin and gender as covariates was performed.
The final model was tested for the proportional hazards
assumption using time-dependent covariates.
In a first step, patients were divided into 2 groups
regarding CRP-values: One group with CRP 10 mg/liter
(normal CRP value at our hospital) and one group with CRP
10 mg/liter. Secondly, we chose to subdivide the group
with elevated CRP further in one group with CRP 10 to 49
mg/liter and one with CRP 50 mg/liter.
For univariate analyses of all other laboratory analyses,
the patients were divided into two groups: One group with
values considered being normal at our hospital and one group
with pathologic values (according to the Department of Clin-
ical Chemistry, University Hospital, Linko¨ping, Sweden).
Statistical analysis was performed using SPSS version 15.0.
RESULTS
Three-hundred-thirteen consecutive patients with NSCLC
stage IIIB/IV who received palliative first-line chemotherapy
were identified. Twenty-four patients were excluded from the
analysis for reasons shown in Figure 1. The remaining 289
patients were included in statistical analysis.
Patient characteristics are shown Table 1. The median
age at start of treatment was 68 years (range, 38–89). The
majority of patients were male (55%), had stage IV disease
(68%) and were in PS 0 or 1 (67%). Forty-nine percent had
adenocarcinoma. Thirteen patients (4.5%) received antibi-
otics at onset of chemotherapy. In two cases, it was not
clear if the patients were treated with antibiotics or not
(0.7%).
Eight-six percent of the patients were current or
former smokers. One hundred forty-four patients (50%)
were smoking at start of treatment. At start of chemother-
apy, normal CRP-values (10 mg/liter) were found in 83
patients (Table 2). Of those with elevated CRP-levels (206
patients, 71%), the majority had CRP-levels between 10
and 49 mg/liter (Table 3). Other laboratory values are
shown in Table 2.
TABLE 2. Clinicopathological Factors and Univariate Survival Analysis
Patients n Survival (mo) Median (95% CI) Hazard Ratio (95% CI) p (Log Rank Test)
Age
0.3170 163 7.1 (5.0–9.2) 1
70 126 7.4 (5.6–9.3) 0.88 (0.69–1.12)
Gender
0.032Male 158 7.0 (6.1–7.9) 1
Female 131 8.6 (6.0–11.2) 0.77 (0.60–0.98)
Stage
0.004IIIB 93 9.3 (6.9–11.8) 1
IV 196 6.6 (5.5–7.7) 1.46 (1.13–1.90)
Performance status
0.0010–1 194 10.0 (8.4–11.6) 1
2 95 5.4 (3.9–6.9) 2.23 (1.72–2.89)
Smoking
0.001Non-smokers 145 10.4 (8.0–12.7) 1
Current smokers 144 6.6 (5.2–8.1) 1.56 (1.22–1.98)
Never smokers 40 11.5 (6.2–16.7) 1 0.001
Ever smokers 249 7.2 (6.1–8.3) 1.80 (1.25–2.59)
CRP
0.00110 mg/liter 83 11.3 (8.7–13.9) 1
10 mg/liter 206 6.3 (5.2–7.5) 1.67 (1.28–2.19)
Albumin
0.00136 g/liter 181 6.1 (4.9–7.2) 1
36 g/liter 108 10.6 (9.5–11.6) 0.59 (0.46–0.75)
LDH
0.0093.5 kat/liter 54 10.5 (7.7–13.2) 1
3.5 kat/liter 233 6.8 (5.7–7.9) 1.52 (1.11–2.09)
Missing values 2
White cell count
0.0018.8  109/liter 108 10.5 (8.5–12.5) 1
8.8  109/liter 181 6.3 (4.8–7.8) 1.64 (1.28–2.11)
Hemoglobin
0.007117 g/liter 62 4.2 (3.2–5.2) 1
117 g/liter 227 8.8 (7.1–10.4) 0.67 (0.50–0.90)
CRP, C-reactive protein; LDH, lactate dehydrogenase; CI, confidence interval.
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At the time for analysis, 272 patients (94%) had died.
Median follow-up time was 42.9 months (range, 14.2–74.3).
Median survival time was 7.4 months.
On univariate survival analysis, patients with elevated
CRP levels had a 67% increase of mortality risk (p  0.001)
compared with the group with normal CRP-levels (Table 2).
When patients with elevated CRP-levels were further
grouped according to the extent of CRP-elevation (10
mg/liter, 10–49 mg/liter, 50 mg/liter), higher levels indi-
cated worse prognosis (Table 3, Figure 2). The differences
were statistically significant.
We also found significant survival differences when
dividing patients according to smoking habits. Current smok-
ers at start of treatment had a 56% higher risk of death (p 
0.001) than nonsmokers (never-smokers  former smokers,
Figure 3). Ever smokers (smokers or former smokers) had a
worse prognosis than never-smokers (HR 1.80, p 0.001).
Even PS (p  0.001), albumin (p  0.001), white cell count
(p  0.001), lactate dehydrogenase (p  0.009), tumor stage
(p  0.004), hemoglobin (p  0.007), and gender (p 
0.032) were prognostic for survival in univariate survival
analysis (Table 2). No significant difference was found in
survival between patients 70 years and patients 70 years.
On multivariate analysis, CRP, smoking status at start
of treatment, PS, stage and albumin were independent prog-
nostic factors for survival (Table 4). The prognostic value of
albumin decreased with time. The hazard ratio of 0.71 rep-
resents the average value over the follow-up time.
Finally, we grouped patients by combining CRP level
(normal versus elevated) and smoking status (current smokers
versus nonsmokers). Nonsmokers with normal CRP had best
prognosis with median survival time of 13.8 months. Patients
with elevated CRP who smoked at start of treatment had
worst prognosis with a median survival time of 5.1 months
(Figure 4, Table 5).
DISCUSSION
Two hundred eighty-nine consecutive patients with
advanced NSCLC were included in this analysis of prognos-
tic factors. All patients were in PS 0–2 and received first-line
chemotherapy with palliative intent. At the time for analysis,
FIGURE 2. Kaplan-Meier survival curves when
patients were grouped according to C-reactive
protein (CRP) levels.
TABLE 3. Survival According to CRP Levels
CRP (mg/Liter) Patients n
Survival (mo) Median
(95% CI) Hazard Ratio (95% CI) p (Log Rank Test)
10 83 (29%) 11.3 (8.7–13.9) 1
10–49 127 (44%) 8.2 (6.4–10.1) 1.38 (1.03–1.84) 0.030
50 79 (27%) 3.6 (2.9–4.3) 2.61 (1.88–3.61) 0.001
Total 289 (100%) 7.4 (6.1–8.8)
CRP, C-reactive protein; CI, confidence interval.
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94% of the patients had died. Patient characteristics and
survival data in this study population were similar to those
reported in studies of chemotherapy in advanced NSCLC.
Besides well-known prognostic factors as tumor stage
and PS, we found that CRP-levels 10 mg/liter and smoking
status at start of treatment were independent predictors of
survival in univariate analysis. Smoking status had impact on
prognosis, both when we compared current smokers with
patients who did not smoke, and when we compared ever
smokers with never-smokers. Survival for patients younger or
older than 70 years was similar. The gender difference, found
in univariate survival analysis, disappeared in multivariate
analysis. Both CRP and smoking remained independently
associated with survival in multivariate analysis.
The amount of prognostic factors studied in lung cancer
is extensive. In their review of the literature published be-
tween 1990 and 2001, Brundage et al.3 criticized the great
variation in the published literature. There are variations in
study populations, variations in the type of statistical analysis,
variations in the type of treatment, and variations in the
prognostic factors included in the analyses. Most of the
studies on smoking as a prognostic factor in lung cancer
include patients in various stages. In addition, patients often
received different kinds of treatment with both curative and
palliative intent. CRP as a prognostic factor in patients with
advanced NSCLC has only been studied in heterogeneous
groups of patients without taking treatment into consider-
ation.9,17
To our knowledge, this is the first study analyzing the
prognostic value of both CRP and smoking in patients with
NSCLC stage IIIB/IV receiving palliative first-line chemo-
therapy. Information on smoking status can easily be ob-
tained from the patient and CRP level is usually part of
routine blood analyses. Thus, in contrast to many other
prognostic factors, information on these two factors is readily
available for the clinician.
The major strength of this study is a uniform patient
population with respect to diagnosis, stage, and treatment.
Long follow-up time reduced the number of censored events.
A weakness is that the analysis was performed retro-
spectively. Furthermore, patients were treated with various
FIGURE 3. Kaplan-Meier survival curves for cur-
rent smokers versus current nonsmokers at start of
chemotherapy.
TABLE 4. Multivariate Survival Analysis (Cox Proportional
Hazards Model)
Variables Hazard Ratio (95% CI) p (Log Rank Test)
Stage 0.001
IIIB 1
IV 1.75 (1.33–2.29)
Performance status 0.001
0–1 1
2 1.80 (1.37–2.36)
Smoking 0.001
Non-smokers 1
Current smokers 1.52 (1.19–1.94)
CRP 0.008
10 mg/liter 1
10 mg/liter 1.50 (1.11–2.02)
Albumin 0.013
36 g/liter 1
36 g/liter 0.71 (0.55–0.93)
Gender 0.13
Male 1
Female 0.83 (0.65–1.06)
CRP, C-reactive protein; CI, confidence interval.
Koch et al. Journal of Thoracic Oncology • Volume 4, Number 3, March 2009
Copyright © 2009 by the International Association for the Study of Lung Cancer330
types of chemotherapy. However, the majority of patients
(71%) received carboplatin  gemcitabine.
Inflammation seems to play an important role in cancer.
The exact role of CRP in the complicated inflammatory
response is not clear. CRP is a nonspecific marker and is also
elevated in bacterial infections.6 In clinical practice, it is not
always possible to find out if a CRP elevation is caused by an
infection or if it is part of the cancer disease. Other clinical
symptoms are taken into account and may result in treatment
with antibiotics, if an infection is suspected. We chose to
register use of antibiotics as an indirect indicator for an
existing infection. Only 13 patients (4.5%) in this study were
treated with antibiotics at start of chemotherapy. The retro-
spective character of our study did not permit other criteria
for the diagnosis of bacterial infection and the presence of
infections may have been underestimated. Our data indicate,
however, that infection was an unlikely explanation for CRP
elevation in most of the patients.
The systemic inflammatory response, represented by
elevation of CRP levels, had impact on survival and quality
of life in a study of 106 patients with stage III and IV
NSCLC.9,18 The results of our study confirm an association
between CRP and prognosis.
As many as 50% of the patients in this study were
current smokers at start of treatment. Smokers had a
significantly shorter survival time than nonsmoking pa-
tients. We chose to group patients in two ways, according
to life-time exposure to tobacco (never-smokers versus
ever smokers) and according to smoking status at treat-
ment start (current smokers versus current nonsmokers).
Never-smokers were included in the group of current
nonsmokers. Prognostic significance of smoking was
shown in both comparisons.
Janjigian et al.23 showed that increased cigarette smok-
ing was associated with decreased survival in 2013 patients
with stage IIIB/IV NSCLC. There was, however, no infor-
mation on treatment in that study. In a study including both
patients with NSCLC and small cell lung cancer, the cigarette
burden had negative impact on survival in patients receiving
platinum-based chemotherapy.25 Both patients who were
treated with palliative and curative intent were included.
Experimental studies with a panel of human NSCLC cell
lines have shown that nicotine inhibits apoptosis induced by
gemcitabine, cisplatin and paclitaxel.26
Thus, both exposition to tobacco before start of treat-
ment or interaction of nicotine with chemotherapy might
provide possible explanations for smokers having worse
prognosis. The question if tobacco exposition before or con-
tinued smoking after treatment start is crucial cannot be
answered by this study.
Our findings indicate that CRP level and smoking
history are relevant in the reporting of studies of chemother-
apy in advanced NSCLC.
FIGURE 4. Survival when patients were grouped
by combining C-reactive protein (CRP) and smok-
ing status at start of chemotherapy.
TABLE 5. Survival When Patients Were Grouped by
Combining CRP and Smoking Status (Current Smokers
Versus Current Nonsmokers) at Start of Chemotherapy
Patients n
Survival (mo)
Median (95% CI)
CRP 10 mg/liter, non-smokers 45 13.8 (11.3–16.2)
CRP 10 mg/liter, smokers 38 9.6 (6.1–13.0)
CRP 10 mg/liter, non-smokers 100 7.4 (5.4–9.4)
CRP 10 mg/liter, smokers 106 5.1 (3.7–6.6)
CRP, C-reactive protein; CI, confidence interval.
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In conclusion, CRP level and smoking history provide
prognostic information in patients with advanced NSCLC
receiving palliative chemotherapy in addition to established
prognostic factors such as stage and PS. Interventional trials
of antiinflammatory treatment and smoking cessation support
could be of interest to elucidate possible cause and effect
relationships.
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